Welcome to our dedicated page for Cabaletta Bio news (Ticker: CABA), a resource for investors and traders seeking the latest updates and insights on Cabaletta Bio stock.
Cabaletta Bio, Inc. (Nasdaq: CABA) is a clinical-stage biotechnology company pioneering engineered T cell therapies for autoimmune diseases. This page serves as the definitive source for official updates on clinical trials, research advancements, and corporate developments related to their innovative CAART and CARTA platforms.
Investors and researchers will find curated press releases detailing progress across multiple Phase 1/2 trials targeting conditions including lupus, myositis, and pemphigus vulgaris. Our collection features updates on therapeutic mechanisms that selectively eliminate pathogenic B cells while preserving healthy immune function.
The resource covers essential developments including trial design innovations, manufacturing process improvements, and strategic collaborations. All content is rigorously verified to ensure accuracy in reporting on this cutting-edge approach to autoimmune treatment.
Bookmark this page for streamlined access to Cabaletta Bio's latest milestones in developing potentially curative therapies. Check regularly for updates on clinical programs demonstrating the company's commitment to transforming autoimmune disease management.
Cabaletta Bio (NASDAQ: CABA) reported Q3 2024 financial results and business updates. The company has 40 U.S. clinical sites actively recruiting patients across its RESET clinical trials, with 16 patients enrolled and 10 dosed as of November 12. Clinical data from RESET-Myositis, RESET-SLE, and initial data from RESET-SSc trials will be presented at ACR Convergence 2024. The company received EMA CTA authorization for CABA-201 in lupus, expanding into Europe. Cash position stands at $183.0 million as of September 30, 2024, expected to fund operations into first half of 2026.
Cabaletta Bio (Nasdaq: CABA), a clinical-stage biotechnology company developing curative targeted cell therapies for autoimmune diseases, announced its participation in Guggenheim's Inaugural Healthcare Innovation Conference. The company will engage in a fireside chat on Monday, November 11, 2024, at 10:00 a.m. ET in Boston, MA.
The presentation will be accessible through a live webcast on the News and Events section of Cabaletta's website, with replays available for 30 days following the event.
Cabaletta Bio (Nasdaq: CABA) announced two presentations at the upcoming American College of Rheumatology (ACR) Convergence 2024, featuring new and updated clinical data on CABA-201, their 4-1BB-containing fully human CD19-CAR T cell investigational therapy. The presentations will cover:
1. An oral presentation on the safety and efficacy of CABA-201 in patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-Myositis™ and RESET-SLE™ Clinical Trials.
2. A poster presentation on correlative studies of CABA-201 in the same patient groups.
The ACR Convergence 2024 will be held from November 14-19, 2024, in Washington, D.C. Presentation materials will be available on Cabaletta Bio's website following the event.
Cabaletta Bio (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing curative targeted cell therapies for autoimmune diseases, has announced its participation in four major investor conferences in September 2024:
- Morgan Stanley 22nd Annual Global Healthcare Conference on September 4
- 2024 Wells Fargo Healthcare Conference on September 5
- H.C. Wainwright 26th Annual Global Investment Conference on September 11
- 2024 Cantor Fitzgerald Global Healthcare Conference on September 17
The company will participate in fireside chats at each event. Live webcasts of the presentations will be available on Cabaletta Bio's website, with replays accessible for 30 days after each event.
Cabaletta Bio reported its Q2 2024 financial results and provided a business update. Notable highlights include:
- Enrollment of nine patients as of August 5, 2024, in the RESET™ clinical development program, with 22 U.S. clinical sites now enrolling.
- Upcoming clinical data expected in 2H24 for RESET-Myositis™, RESET-SLE™, RESET-SSc™, and RESET-MG™ trials.
- An LN patient experienced a dose-limiting toxicity which resolved quickly, allowing the study to proceed without delays.
- Agreements with Lonza and Cellares to enhance manufacturing and scalability.
- Cash, cash equivalents, and short-term investments totaling $203.2 million, supporting operations into 1H 2026.
Financially, R&D expenses rose to $23.4M from $11.8M YoY, and G&A expenses increased to $6.9M from $4.1M YoY. The company also welcomed Dr. Sarah Yuan as Chief Technology Officer to advance its manufacturing strategy.
Cabaletta Bio, a clinical-stage biotech firm focusing on curative cell therapies for autoimmune diseases, announced its CEO, Steven Nichtberger, will participate in the Stifel 2024 Virtual Cell Therapy Forum. This event is scheduled for July 9, 2024, at 1:00 p.m. ET. Interested parties can access a live webcast and replay of the fireside chat via the company's website. The webcast will remain available for 30 days.
Cabaletta Bio reported positive initial clinical data from its Phase 1/2 RESET-Myositis and RESET-SLE trials for its investigational therapy, CABA-201.
Key findings include no serious adverse events, no CRS or ICANS, and no infections in either of the first two patients. The therapy showed the expected CAR T cell expansion and contraction with complete B cell depletion by day 15 post-infusion.
Both patients showed improvement in disease measures and were able to discontinue all maintenance therapies, except for a planned steroid taper in one case. The trials indicate a potential immune system reset, with immature, naïve B cell repopulation observed at week 8 in one patient.
The company continues to enroll patients and expects to report more data in the second half of the year. A conference call and webcast are scheduled for June 14, 2024, at 8:00 a.m. ET to discuss these findings.
Cabaletta Bio, a clinical-stage biotech firm specializing in curative targeted cell therapies for autoimmune diseases, announced its CEO, Steven Nichtberger, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024. The event will be held at 11:00 a.m. ET in New York, NY. A live webcast of the presentation will be accessible on Cabaletta Bio's website, with replays available for 30 days.
Cabaletta Bio (Nasdaq: CABA) announced its Q1 2024 financial results and provided business updates. Key highlights include the absence of CRS or ICANS in the initial patients treated in the RESET-Myositis and RESET-SLE trials, with clinical data expected at the EULAR 2024 Congress. The company is expanding the CABA-201 trial to dermatology with the RESET-PV sub-study and exploring apheresis-free manufacturing methods. Financially, Cabaletta's R&D expenses rose to $22 million, and G&A expenses increased to $6.1 million. The company holds $223.8 million in cash and investments, projected to fund operations into 2026.
Cabaletta Bio, a clinical-stage biotechnology company, will participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ. The event is scheduled for May 20, 2024, in New York, NY. The company focuses on developing curative targeted cell therapies for patients with autoimmune diseases.
FAQ
What is the current stock price of Cabaletta Bio (CABA)?
What is the market cap of Cabaletta Bio (CABA)?
